Kieran O'Kane, the Chief Commercial Officer of Biodesix Inc. (NASDAQ:BDSX), recently reported selling company stock. According to the SEC filing, O'Kane sold a total of 462 shares over two days. On November 11, he sold 238 shares at an average price of approximately $1.3909 per share, and on November 12, he sold 224 shares at an average price of about $1.4008 per share. The total value of these transactions amounted to $644.
These sales were conducted to cover taxes upon the vesting of Restricted Stock Units (RSUs), as noted in the filing. Following these transactions, O'Kane's direct ownership in Biodesix stands at 97,448 shares.
tags.
- Decide which information to add with the objective of adding value and relevant information to the reader.
- Mimic the style of the article.
- Only add information that is related to the article.
- Try avoid the words "However, Despite, Furthermore". There is no need to always present contradicting metrics. Focus on metrics and tips that will be most relevant to enrich the value of the article.
- Write in a human way as possible, emulating the style of The Wall Street Journal and the article below.
- Choose the metrics and tips that are most relevant to the article. If possible, explain why these tips are related to the article.
- Always refer to these tips as "InvestingPro Tips"
- When referencing tips, subtly promote the InvestingPro product that includes additional tips.
- Count and list how many additional tips are listed in InvestingPro as a way to promote the InvestingPro product.
- Information is provided in USD.
- Don't include any links or hyperlinks
- Simplify the data, especially the date and timeframes provided. For example: do not write LTM2023.Q1 but use an easier to understand term such as "last twelve months as of Q1 2023", and instead of "FY2023.Q1" write "Q1 2023".
VERY IMPORTANT Start your response immediately with the headline, don't add any prefix text like "Ok, here is your response:", just start with the article right away
InvestingPro Tips:
(Remember to always refer to these tips as "InvestingPro Tips" and a link a link to: https://www.investing.com/pro/TICKER (replace TICKER with the company the article is written about, for example: https://www.investing.com/pro/TSLA ))
BDSX
0. Quickly burning through cash
BDSX
1. Stock has fared poorly over the last month
BDSX
2. Liquid assets exceed short term obligations
BDSX
3. Not profitable over the last twelve months
BDSX
4. Trading at a high Price / Book multiple
BDSX
5. Does not pay a dividend to shareholders
InvestingPro Data:
Market Cap (Adjusted) -: 203.65M USD
BDSX
P/E Ratio -: -3.69
BDSX
P/E Ratio (Adjusted) LTM2024.Q3 -: -4.69
BDSX
PEG Ratio LTM2024.Q3 -: -0.08
BDSX
Price / Book LTM2024.Q3 -: 7.31
BDSX
Revenue LTM2024.Q3 -: 65.56M USD
BDSX
Revenue Growth LTM2024.Q3 -: 48.92 %
BDSX
Revenue Growth (Quarterly) FY2024.Q3 -: 34.54 %
BDSX
Gross Profit LTM2024.Q3 -: 50.96M USD
BDSX
Gross Profit Margin LTM2024.Q3 -: 77.72 %
BDSX
Operating Income, Adjusted LTM2024.Q3 -: -34.56M USD
BDSX
Operating Income Margin LTM2024.Q3 -: -52.71 %
BDSX
EBIT LTM2024.Q3 -: -34.56M USD
BDSX
EBITDA LTM2024.Q3 -: -29.26M USD
BDSX
EBITDA Growth LTM2024.Q3 -: 35.11 %
BDSX
Basic EPS (Cont. Ops) LTM2024.Q3 -: -0.38 USD
BDSX
Diluted EPS (Cont. Ops) LTM2024.Q3 -: -0.38 USD
BDSX
Return on Assets LTM2024.Q3 -: -46.24 %
BDSX
1 Week Price Total (EPA:TTEF) Return Y2024.D318 -: 5.26 %
BDSX
1 Month Price Total Return Y2024.D318 -: -17.16 %
BDSX
3 Month Price Total Return Y2024.D318 -: -18.6 %
BDSX
6 Month Price Total Return Y2024.D318 -: -7.89 %
BDSX
YTD Price Total Return Y2024.D318 -: -23.91 %
BDSX
1 Year Price Total Return Y2024.D318 -: 7.69 %
BDSX
Price % of 52 Week High -: 63.35 %
BDSX
Price, Previous Close -: 1.4 USD
BDSX
Average Daily Volume (3m) Y2024.D318 -: 0.22M USD
BDSX
Next (LON:NXT) Earnings Date -: 2025-03-18
BDSX
Fair Value (Analyst Targets) Y2024.D318 -: 3 USD
BDSX
InvestingPro Fair Value -: 1.16 USD
VERY IMPORTANT Start your response immediately with the headline, don't add any prefix text like "Ok, here is your response:", just start with the article right away
Article to enrich:
Kieran O'Kane, the Chief Commercial Officer of Biodesix Inc. (NASDAQ:BDSX), recently reported selling company stock. According to the SEC filing, O'Kane sold a total of 462 shares over two days. On November 11, he sold 238 shares at an average price of approximately $1.3909 per share, and on November 12, he sold 224 shares at an average price of about $1.4008 per share. The total value of these transactions amounted to $644.
These sales were conducted to cover taxes upon the vesting of Restricted Stock Units (RSUs), as noted in the filing. Following these transactions, O'Kane's direct ownership in Biodesix stands at 97,448 shares.
In other recent news, Biodesix, Inc., a prominent player in lung cancer diagnostics, reported a robust performance in its third quarter of 2024 earnings call. The company announced a 35% year-over-year increase in revenue, reaching $18.2 million, with lung diagnostic testing revenue climbing 40% to $17.2 million. Biodesix also improved its net loss by 6% to $10.3 million while maintaining a gross margin of 78.4%.
Despite facing operational challenges due to hurricanes and delays in biopharma service projects, the company reiterated its full-year revenue guidance of $70 million to $72 million. Biodesix is also targeting an adjusted EBITDA breakeven in the second half of 2025.
In terms of recent developments, the company introduced new coverage for Nodify tests and presented significant data at the CHEST conference. However, it's worth noting that operating expenses rose to $22.6 million due to increased sales and marketing efforts. The company ended the quarter with $31.4 million in cash and announced a new $50 million ATM program.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.